Upload
others
View
4
Download
0
Embed Size (px)
Citation preview
CLINICAL PATHWAY
Page 1 of 13
HEMOPHILIA AND VON WILLEBRAND DISEASE EMERGENCIES
ALGORITHM. Hemophilia and von Willebrand Disease Factor Replacement Therapy
Inclusion Criteria:
Diagnosis of Hemophilia
Exclusion Criteria:
Patients with Planned
Admission
Patient presents to ED
Is factor replacement indicted?
(see indications to the left)
Did patient bring clotting
factor?
Pharmacist to verify factor. If
pharmacist is not available,
nurse to verify at bedside.
Allow patient/caregiver to
reconstitute and administer
own product.
Off Pathway. Continue care as clinically
indicated
What does the patient use at
home? If not known, review
EHR, see table below for
substitutions, and/or consult
hematologist.
Is preferred product available
in pharmacy?Initiate factor replacement
therapy with preferred product
Initiate factor replacement therapy with
substitute CHCO formulary product below
(see Table 1 for appropriate substitute):
· If patient needs factor VIII use Advate
· If patient needs factor IX use BeneFIX
· If patient needs factor VIII use w/vWF
Humate-P
· If patient needs FEIBA
· If patient needs rFVIIa
· If patient needs dose of DDAVP
!
Goal for factor
replacement
is 30 minutes or less
for suspected head bleeds and
60 minutes or less for suspected
bleeding in areas other than the
head
Pearls:
P1: When in doubt, administer clotting factor replacement
therapy
P2: Clotting factor replacement therapy should be infused
prior to any labs, radiologic studies, or procedures
P3: Notify on-call hematologist immediately
P4: Patient or caregiver s suspicion of bleeding-related
problem is sufficient to initiate factor replacement therapy
P5: Only order diagnostic tests if they will change the
outcome
P6: Allow patient to use own product
P7: Patients with factor IX deficiency are at risk for
anaphylaxis
P8: Round dose up to the nearest vial size and give the
entire vial (do not throw away extra factor) unless
Hemophilia A patient weighing less tan 5 kg or Hemophilia
B patients weighing less than 2 kg
NO
Yes
NO
YES
NO
YES
Check patient s problem list for
bleed plan documented under
Hemophilia Diagnosis or von
Willebrand disease
Indications for Factor Replacement Therapy
· Suspected bleeding into a joint or muscle
· Any significant injury to the head, neck, mouth or eyes,
or evidence of bleeding in those areas
· Any new or unusual headache, particularly one
following trauma
· Severe pain or swelling at any site
· All open wounds requiring surgical closure, wound
adhesive, or Steri-Strips
· History of an accident or trauma that might result in
internal bleeding
· Any invasive procedure or surgery
· Heavy or persistent bleeding from any site
· Gastrointestinal bleeding
· Acute fractures, dislocations and sprains
Alert CHCO inpatient pharmacy to order
patients preferred product from HTC (303-
724-0168) if patient is admitted
Monday-Friday 8am-5pm, factor available
within two hours
All other hours, factor available within 4
hours
!
If patient is on
emicizumab-kxwh please
see problem list and consult
hematology
CLINICAL PATHWAY
Page 2 of 13
TABLE OF CONTENTS
Algorithm
Target Population
Clinical Management
Clinical Assessment
Laboratory and Radiology Studies
Therapeutics
Admission Criteria
Discharge Criteria
Follow-Up
Table 1 Product Replacement Guide
Table 2 Desmopressin (DDVAP = CHCO formulary) Dosing
Table 3 Anti-Fibrinolytics
References
Clinical Improvement Team
TARGET POPULATION
Inclusion Criteria
· Patients with a diagnosis of hemophilia or von Willebrand disease and history of injury, complaint of pain, or other concern for bleeding
Exclusion Criteria
· Patients with planned admission
CLINICAL MANAGEMENT
Initial Triage
Triage should be urgent. Delays in administering factor concentrate treatment significantly affect morbidity and mortality in individuals with hemophilia or von Willebrand disease1
The six major sites for serious bleeding which threaten life, limb, or function are2:
· Intracranial
· Spinal cord
· Throat/mouth
· Intra-abdominal
· Limb compartments
· Ocular
All of the above require immediate assessment and intervention, and are characterized by2
CLINICAL PATHWAY
Page 3 of 13
· Bleeding into an enclosed space
· Compression of vital tissues
· Potential loss of life, limb, or function
CLINICAL ASSESSMENT
· Treatment for a suspected bleeding episode is based on clinical history. Many physical exam findings tend to be normal in the early phases of most hemophilic bleeds. Spontaneous bleeding is common in individuals with severe disease. When in doubt, administer clotting factor replacement therapy1
· Treatment decisions should be based on the suspicion of a bleeding-related problem, not a confirmed diagnosis of one1
· If, in their experience, the patient or caregiver suspects occult bleeding is occurring, administer clotting factor replacement. Patients often are instructed in and/or carry with them appropriate factor replacement dosing guidelines as advised by their treating hematologist1
· Consultation with the patient's hematologist or a regional hemophilia treatment center professional is strongly advised; however, this should not delay administration of clotting factor1
Signs and symptoms2:
Head:
· Early neurological symptoms may not be evident due to the slow, oozing nature of hemophilia bleeding
· Headache with increasing severity
· Irritability
· Vomiting
· Seizures
· Vision problems
· Focal neurological deficits
· Stiff neck
· Altered mental status or change in level of consciousness
Joint bleeding:
· Pain
· Restricted movement
· Swelling
· Warmth
· Erythema on and around the joint
· Patient may report symptoms of bubbling or tingling sensation with no physical signs
· Later symptoms may include:
o A feeling of fullness within the joint
o Moderate to severe pain
Muscle/Soft Tissue bleeding:
· Any muscle group may be subject to bleeding. Common bleeding sites include upper arm, forearm, thigh, calf muscles, abdominal wall muscles, and iliopsoas muscles
CLINICAL PATHWAY
Page 4 of 13
· Abdominal muscles generally do not have observable swelling, but may have a palpable mass, rigidity, and pain
· Lower abdominal or groin pain, especially with signs of nerve compression may indicate an iliapsoas bleed
· Other muscles may exhibit:
o Warmth
o Pain
o Swelling
· Soft tissue bleeds usually do not require aggressive treatment. Superficial hematomas and bruises may appear anywhere on the body and, if they do not threaten function and mobility, they do not need to be treated
Gastrointestinal/Urinary Tract bleeding:
· Abdominal pain
· Flank pain
· Hematuria
· Melena
· Vomiting blood
· Dropping hemoglobin
o Steady dropping hemoglobin may indicate bleed in abdominal cavity
o Dramatic drop in hemoglobin following trauma may indicate rupture of liver, spleen, or pancreas
Mucous Membrane/Oral bleeding:
· Pain
· Swelling
· Difficulty swallowing
· Difficulty breathing
· Vomiting triggered by swallowed blood
· Patient may report the sensation of postnasal drip (blood running down back of throat from posterior epistaxis) or may report tasting blood
LABORATORY STUDIES | IMAGING
Diagnostic tests are only indicated if they will change outcome
· Clotting factor replacement therapy should be given before any diagnostic studies (radiographs, CT scans etc.) are performed in the evaluation of a suspected bleeding problem, especially in the case of head trauma or suspected intracranial hemorrhage. For routine joint bleeding, no radiographic studies are indicated1
· If invasive procedure (lumbar puncture, arterial blood gas, arthrocentesis, etc.) or surgery is necessary, factor replacement therapy must be administered in the emergency department beforehand1. Factor will be distributed and circulating 15 minutes post IV push
· For an individual with known hemophilia, routine laboratory studies (PT, PTT, factor levels), are not indicated in the treatment of a routine bleeding episode unless requested by the patient s hematologist. The clinical severity of a patient's hemophilia is gauged by his or her baseline clotting factor level, a value that remains fairly constant throughout that person's life1
CLINICAL PATHWAY
Page 5 of 13
THERAPEUTICS (SEE TABLES 1, 2, AND 3 FOR DOSING)
· Refer to bleed treatment plan documented in patient s Problem List under hemophilia diagnosis. A unique plan will be documented in the Problem List for all known hemophilia patients seen by CHCO hematology
· Most bleeds will require factor replacement except for bruises and minor soft tissue injuries that do not impact function and mobility
· Treatment for bleeding involves replacing the deficient factor as the first course of action. This requires intravenous infusion of factor concentrates. Specific doses, additional drugs, and medical interventions depend upon the site and severity of bleeding. Once factor replacement therapy has been infused, diagnostic procedures and examinations can begin
· Goal time (from presentation to Anschutz CHCO emergency department) for start of administration of factor replacement is 30 minutes or less for suspected head bleeds and 60 minutes or less for suspected bleeding in areas other than the head
· Indications for factor replacement therapy1:
o Suspected bleeding into a joint or muscle
o Any significant injury to the head, neck, mouth or eyes, or evidence of bleeding in those areas
o Any new or unusual headache, particularly one following trauma
o Severe pain or swelling at any site
o All open wounds requiring surgical closure, wound adhesive, or Steri-Strips
o History of an accident or trauma that might result in internal bleeding
o Any invasive procedure or surgery
o Heavy or persistent bleeding from any site
o Gastrointestinal bleeding
o Acute fractures, dislocations and sprains
· Considerations for factor replacement therapy:
o If a patient with hemophilia or the parent of a patient with hemophilia brings clotting factor with them to the emergency department, allow them to use it. The identity and integrity of a patient s own medication should be verified and documented by a Children s Hospital Colorado pharmacist prior to administration. In the event a pharmacist is not available to conduct this review promptly, the patient s own medication may be checked by the nurse caring for the patient. The patient or caregiver should be permitted to reconstitute the product and administer it whenever possible. Individuals with bleeding disorders are encouraged to have an emergency dose of factor concentrate or DDAVP in their home and to take it with them when they travel. In those situations when a patient does not bring their own clotting factor concentrate, Anschutz CHCO emergency department must be prepared to provide clotting factor replacement. Anschutz CHCO emergency department must have ready access to factor replacement products so that they are available within one hour of the patient's arrival1
o Factor replacement must be administered intravenously by IV push over 1 to 2 minutes1
o Dose factor up to the "closest vial" by size/assay and infuse the full content of each reconstituted vial. A moderate excess of factor concentrate will not create a hypercoaguable state but will prolong the therapeutic level of the product administered; thus it is prudent to round up 1
o For individuals with inhibitors (antibodies to factor VIII or IX), treatment decisions may be more complicated. Consult hematology
o When treating an individual with mild hemophilia A who is responsive to desmopressin (CHCO formulary = DDAVP), the dose and prior responsiveness are usually known
CLINICAL PATHWAY
Page 6 of 13
o The most experienced IV therapist or phlebotomist should perform any venipuncture. Traumatic venipunctures and repeated needle sticks cause painful hematomas that may limit further IV access and lead to compartment syndrome1
· Factor infusion kits usually include butterfly needles, which are preferred. If IV access is necessary in otherwise hemodynamically stable patients, the smallest possible gauge needle should be utilized (25g butterfly needles in young infants, 23g butterfly needles in older children and adults)1
o In any suspected bleeding emergency in which the clotting factor level of an individual with hemophilia is unknown, the factor level should be assumed to be 0%1
o Intramuscular injections should be avoided whenever possible. If they must be given, factor replacement therapy should precede the injection. Parenteral agents should be given intravenously or subcutaneously. Tetanus immunizations may be administered subcutaneously1
o Tourniquets should not be applied tightly to extremities because they may cause bleeding1
o Analgesics and Antipyretics:
· Aspirin and aspirin-containing products are contraindicated in individuals with hemophilia
· Acetaminophen and/or other pain medications (such as morphine or hydrocodone) may be used for analgesia
· Non-steroidal anti-inflammatory drugs may be carefully administered to select patients, such as
· individuals with chronic arthritic pain who are not actively bleeding or being treated for a recent bleeding problem1
o If an individual with hemophilia is bleeding and requires transportation to another facility for definitive care, all efforts should be made to replace the deficient clotting factor before transport1
Hemophilia A without Inhibitor
The treatment of choice for individuals with hemophilia A (factor VIII deficiency) is recombinant factor VIII or the patient s product of choice. Plasma-derived concentrate is a suitable alternative in an emergency situation when recombinant Factor VIII is not available. See: Hemophilia and von Willebrand Disease Factor Replacement Therapy Algorithm
· When bleeding is severe, the appropriate dose of factor VIII is 50 units/kg. If patient weighs less than 5 kg do not exceed 75 units/kg correction when rounding to vial size (in a patient less than 5 kg you may NOT be able to use the entire vial)
· Cryoprecipate and fresh frozen plasma are no longer recommended for treatment of individuals with hemophilia A1
Mild Hemophilia A with Non-Life or Limb Threatening Bleeding
Individuals with mild hemophilia A (factor VIII greater than 5%) who are experiencing non-life or limb threatening bleeding may respond to desmopressin (CHCO formulary = DDAVP) if they have been shown to respond to this treatment previously. Otherwise, treatment is the same as for other individuals with hemophilia A1
· Desmopressin (CHCO formulary = DDAVP)1: 0.3mcg/kg subcutaneously
or
· Desmopressin (CHCO formulary = DDAVP)1: 0.3mcg/kg diluted in 30 mL normal saline infused over 30 minutes
or
· Intranasally via ultra-concentrated nasal spray "Stimate":
o For patients less than 50 kg: 1 spray in one nostril
o For patients greater 50 kg: 1 spray in each nostril
CLINICAL PATHWAY
Page 7 of 13
Hemophilia B without Inhibitor
The treatment of choice for individuals with hemophilia B (factor IX deficiency) is recombinant factor IX or the patient s product they usually receive at home. Plasma-derived concentrate, see list of factor IX products in Table 1, is a suitable alternative in an emergency situation when recombinant Factor IX is not available. See: Hemophilia and von Willebrand Disease Factor Replacement Therapy
· Severe factor IX deficient patients are at risk of anaphylaxis and nephrotic syndrome
· Factor IX recovery is unpredictable (often lower recovery) when using BeneFIX®
· If patient treated with BeneFIX® continues to bleed, check a STAT Factor IX activity and redose
· When bleeding is severe, the appropriate dose of factor IX is 120 units/kg
o If patient weighs less than 2 kg do not exceed 150 units/kg correction when rounding to vial size (in a patient less than 2 kg you may NOT be able to use the entire vial)
· Fresh frozen plasma is no longer recommended for treatment of individuals with hemophilia B. Note that cryoprecipitate does not contain Factor IX1
Hemophilia with Inhibitor
The care of inhibitor patients should be urgently discussed with the patient's hematologist. If an individual with an inhibitor presents in a life- or limb-threatening scenario, the safest immediate action is to prescribe recombinant factor VIIa (rFVIIa) at a dose of 90 mcg/kg or higher (see patients plan in problem list) or activated prothrombin complex concentrates (FEIBA) at 75 units/kg. The patient or family can also provide information on response to therapeutic bypassing agents1
· Patients taking Emicizumab-kxwh should not get FEIBA. Please see patient problem list
Note: In factor IX patients with a history of inhibitors and anaphylaxis do not give factor IX-containing products (FEIBA) unless the bleeding is life-threatening1
Anti-fibrinolytics
· Anti-fibrinolytics are contraindicated in patients with hematuria
· Aminocaproic Acid:
o Can be given PO or IV if needed
o Loading dose: 50 to 200 mg/kg PO or IV every 6 hours for 3 to 10 days. Dose not to exceed 4 grams
o Maintenance dose: 50-100 mg/kg/dose PO or IV every 6 hours
· Tranexamic Acid (TXA):
o 1300 mg orally every 8 hours for 5 days10 mg/kg/dose IV every 6 hours or 10 mg/kg/dose IV once to load then 10/mg/kg/hour IV continuous infusion (maximum 1000 mg/dose)
Other Modalities2 (Evidence quality: D)
1. Protect (bracing)
2. Rest
3. Ice packs
4. Compression (Ace wrap)
5. Elevation
CLINICAL PATHWAY
Page 8 of 13
ADMISSION CRITERIA
Discuss admission with hematologist
DISCHARGE CRITERIA
Discuss discharge plan with hematologist. If patient is to be discharged, determine whether or not to leave the port accessed or PIV in place and provided necessary teaching to caregivers
FOLLOW-UP
Notify patient s hematologist or Hemophilia and Thrombosis Center
Table 1. Product Replacement Guide
Product type Product Name
(Brand) CHCO Stock
Product
Dose for Major Acute Bleed
(Range)¥ Comments
Factor VIII Recombinant
Advate ®
Advate® 50 units/kg¥
(30-50 units/kg)
1 unit of any other brand of Factor VIII is equal to 1 unit of Advate® for maintenance dosing
Adynovate® Afstyla®
Eloctate® Helixate® FS
Kogenate® FS Kovaltry®
Novoeight® Nuwiq® Obizur®
Recombinate ® Xyntha® Xyntha® Solofuse™
Factor VIII plasma
derived with vWF
Alphanate® (for hemophilia A)
Wilate (for hemophilia A)
Advate® 50 units/kg¥
(30-50 units/kg)
1 unit of any other brand of Factor VIII is equal to 1
unit of Advate® for maintenance dosing
Factor IX Recombinant
Alprolix®
BeneFIX®
120 units/kg¥ (50-120 units/kg)
1 unit of any other brand of Factor IX is equal to 1.2
units of BeneFix® for maintenance dosing
BeneFIX®
Idelvion®
Ixinity®
Rebinyn®
Rixubis®
Factor IX plasma derived
AlphaNine SD®
BeneFIX®
120 units/kg¥ (50-120 units/kg)
1 unit of any other brand of Factor IX is equal to 1.2
units of BeneFix® for maintenance dosing
Mononine®
CLINICAL PATHWAY
Page 9 of 13
Factor VIII with vWF Complex
Alphanate® (for VWF disease)
Humate-P® 60 VWF:RCo
units/kg¥ (20-80 units/kg)
Humate-P®
Wilate®
Vonvendi®
Factor VIIa Recombinant
NovoSeven® RT NovoSeven®
RT 90mcg/kg¥
(30-270mcg/kg)
Anti-inhibitor Coagulant Complex
FEIBA NF FEIBA NF 75 units/kg¥
(50-85 units/kg)
*Refer to Black box warning below
*Black Box Warning FEIBA NF: Thrombotic and thromboembolic events have been reported during post-marketing surveillance following infusion of FEIBA VH or FEIBA NF, particularly following the administration of high doses and/or in patients with thrombotic risk factors
¥ Refer to patient s Snapshot in Epic for hemorrhage plan. If available, patient s hemorrhage plan supersedes dose in this chart
¥ Emicizumab-kxwh is the first in a new class of drugs only for people with hemophilia A. It is a novel bi-specific antibody that bypasses FVIII and allows hemophilia A patient with and without inhibitors have high quality prophylaxis. It is not for treating acute bleeding. The phase 3 clinical trial in adults and children with inhibitors showed efficacy, and its use in non-inhibitor patients is pending FDA approval soon. Complications occurred during the trial, all when trying to treat bleeding. They were thrombosis and thrombotic microangiopathy all associated with the improper use of FEIBA. Because of this FEIBA is contraindicated and to treat bleeding the PI dose of rFVIIa is recommended: 90 mcg/kg/dose. Increasing numbers of patients are starting emicizumab-kxwh. Instructions for treating bleeding are in
the Problem List and the Hematologist on call should be notified when treating a patient on emicizumab-kxwh
Table 2. Desmopressin (DDVAP = CHCO formulary) Dosing
Route Dose Subcutaneously 0.3mcg/kg subcutaneously
Intravenously 0.3mcg/kg diluted in 30 mL normal saline infused
over 30 minutes
Intranasally via ultra-concentrated nasal spray "Stimate"
F For patients less than 50 kg: 1 spray in one nostril For patients greater 50 kg: 1 spray in each nostril
CLINICAL PATHWAY
Page 10 of 13
Table 3. Anti-fibrinolytics
Note: Anti-fibrinolytics are contraindicated in patients with hematuria
Product Dosing Aminocaproic Acid: Can be given orally or IV if needed
Loading dose: 50 to 200 mg/kg orally or IV every 6 hours for 3 to 10 days. Dose not to exceed 4 grams Maintenance dose: 50-100 mg/kg/dose orally or IV every 6 hours
Tranexamic Acid (TXA)
Oral: 1300 mg orally every 8 hours for 5 days
IV: 10 mg/kg/dose IV every 6 hours or 10 mg/kg/dose IV once to load then 10/mg/kg/hour IV continuous infusion
CLINICAL PATHWAY
Page 11 of 13
REFERENCES
1. National Hemophilia Foundation. Guidelines for Emergency Department Management of Individuals with Hemophilia. 2006. http://www.hemophilia.org/NHFWeb/MainPgs/MainNHF.aspx?menuid=57&contentid=691.)
2. Emergency Care for Patients with Hemophilia. Third ed: Clarence Printing; 2010
3. American Academy of Pediatrics. Classifying recommendations for clinical practice guidelines. Pediatrics 2004;114:874-7
4. National Heart, Lung, and Blood Institute (NHLBI). The Diagnosis, Evaluation and Management of von Willebrand Disease. 2008. https://www.nhlbi.nih.gov/health-topics/diagnosis-evaluation-and-management-of-von-willebrand-disease
National Heart, Lung, and Blood Institute (NHLBI). Von Willebrand disease (VWD): evidence-based diagnosis and management guidelinesHaemophilia: The Official Journal Of The World Federation Of Hemophilia, 14(2), 171-232. doi:10.1111/j.1365-2516.2007.01643.x
CLINICAL PATHWAY
Page 12 of 13
Clinical pathways are intended for informational purposes only. They are current at the date of publication and are reviewed on a regular basis to align with the best available evidence. Some information and links may not be available to external viewers. External viewers are encouraged to consult other available sources if needed to confirm and supplement the content presented in the clinical pathways. Clinical pathways are not intended to take the place of a physician s or other health care provider s advice, and is not intended to diagnose, treat, cure or prevent any disease or other medical condition. The information should not be used in place of a visit, call, consultation or advice of a physician or other health care provider. Furthermore, the information is provided for use solely at your own risk. CHCO accepts no liability for the content, or for the consequences of any actions taken on the basis of the information provided. The information provided to you and the actions taken thereof are provided on an as is basis without any warranty of any kind, express or implied, from CHCO. CHCO declares no affiliation, sponsorship, nor any partnerships with any listed organization, or its respective directors, officers, employees, agents, contractors, affiliates, and representatives.
CLINICAL IMPROVEMENT TEAM MEMBERS
Michael Wang, MD | Pediatric Hematologist
Timothy Schardt, Pharm D, BCPS| Clinical Pharmacist for Investigational Drug Services and Anticoagulation
Julia Freeman, MD | Pediatric Emergency Medicine
Joni MacKenzie, MS, CPNP | Emergency Clinical Practice Specialist
Claire Zafiropoulos | Clinical Effectiveness
Paige Krack | Clinical Effectiveness
APPROVED BY
Clinical Pathways and Measures Committee - May 9, 2018
Pharmacy and Therapeutics Committee - May 3, 2018
MANUAL/DEPARTMENT Clinical Pathways/Quality
ORIGINATION DATE January 3, 2014
LAST DATE OF REVIEW OR REVISION May 9, 2018
APPROVED BY
Lalit Bajaj, MD, MPH
Medical Director, Clinical Effectiveness
REVIEW/REVISION SCHEDULE
Scheduled for full review on May 9, 2022
CLINICAL PATHWAY
Page 13 of 13